New drug hope for stubborn hives patients
NCT ID NCT05170724
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides remibrutinib, an experimental drug, to adults with chronic spontaneous urticaria (long-term hives) that haven't improved with antihistamines or omalizumab. Participants take the drug as prescribed to help control their symptoms. The goal is to offer access to a potential new treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remibrutinib
- What this could lead to
- If successful, this could offer a new treatment option for people with chronic hives that don't respond to standard therapies.
- What could go wrong
- This is an access program, not a formal trial, so results are not systematically collected. It may not work for everyone, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a diet tame chronic hives in teens?
- Can a new pill silence the itch of chronic hives?
- New drug aims to quiet chronic hives
- New pill for chronic hives enters first human tests
- New pill for chronic hives tested in everyday clinics
- New hope for chronic hive sufferers: phase 3 drug trial shows promise